Third Rock Ventures — Full Portfolio

BiotechCambridge, US

Robert Gould(Executive Officer, Director)

BoardAlan Ezekowitz(Director)inJames Geraghty(Director)James Collins(Director)

Board seatMark Levin· per SEC Form D · $55M raise · filed Jul 2017

Co-investorsForesite Capital

BiotechArlington, US

Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)Kim Brazzell(Executive Officer)Charles McDermott(Executive Officer)

Board seatRobert Tepper· per SEC Form D · $7M raise · filed Aug 2015

Co-investorsLongitude CapitalSR One Capital ManagementYsios CapitalAtlas VentureLux Capital

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.

BiotechSouth San Francisco, US

Bernard Coulie(Executive Officer, Director)Johannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)

BoardKevin Raidy(Director)

Board seatCharles HomcyNeil Exter· per SEC Form D · $62.1M raise · filed Jul 2018

Co-investorsMenlo VenturesAgent Capital

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Board seatNeil ExterBarbara Weber· per SEC Form D · $100.3M raise · filed Nov 2019

Co-investorsBain Capital Life SciencesForesite CapitalNextech Invest

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)Adam Crystal(Executive Officer)Daniella Beckman(Executive Officer)Douglas Barry(Executive Officer)Aaron Davis(Director)

BoardBarbara Weber(Executive Officer, Director)in

Board seatAlexis BorisyReid Huber· per SEC Form D

Co-investorsForesite CapitalNextech InvestNSG Ventures

NASDAQ-listed (VYGR) biotech in Lexington, MA developing AAV gene therapies and antibodies for neurological diseases.

BiotechLexington, US

Robin Swartz(Executive Officer)Alfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)Steven Hyman(Director)James A. Geraghty(Director)Grace Colon(Director)

Board seatMark Levin· per SEC Form D · filed Apr 2015

Co-investorsARCH Venture Partners

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Co-investorsARCH Venture Partners

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine LearningBiotechMedical DevicesSan Francisco, US

Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in

Co-investorsRA CapitalSozo VenturesYosemite

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Michael Naill(Senior Vice President, Process and Product Development)Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)

Co-investorsBain Capital Life SciencesBiotechnology Value FundGV (Google Ventures)

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsBain Capital Life SciencesGV (Google Ventures)

Vibe Bio funds and supports overlooked drug development programs by combining AI and capital to identify promising treatments and reduce funding gaps.

AI & Machine LearningBiotechEnterprise Software

Alok Tayi(CEO & Founder)

Co-investors6th Man VenturesAlleyCorpUndeterred CapitalAlley Robotics Ventures

BiotechSan Mateo, US

Anthony Ford(Executive Officer)Michael Kitt(Executive Officer)Kathleen Sereda Glaub(Executive Officer, Director)

BoardArthur Pappas(Director)Liam Ratcliffe(Director)

Board seatKevin Starr· per SEC Form D · $55M raise · filed Jul 2015

Co-investorsPappas CapitalDomain Associates

BiotechNewton, US

Alexey Margolin(Executive Officer, Director)Louis Brenner(Executive Officer)

BoardAxel Bolte(Director)James Topper(Director)Stephen Kraus(Director)

Board seatRobert Tepper· per SEC Form D · $53M raise · filed Dec 2015

Co-investorsPontifax Venture CapitalFrazier Life Sciences

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)

BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in

Board seatMark Angelino· per SEC Form D · $215M raise · filed Nov 2021

Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG Crossover

BiotechSouth San Francisco, US

Ivana Djuretic(Executive Officer, Director, Promoter)Yik Andy Yeung(Executive Officer, Director, Promoter)

Board seatJeffrey TongReid Huber· per SEC Form D · $55M raise · filed Apr 2024

BiotechAnn Arbor, US

Julia C. Owens(Executive Officer, Director)

BoardCarol Gallagher(Director)James Topper(Director)William Harrington(Director)Randall Whitcomb(Director)

Board seatMary Lynne Hedley· per SEC Form D · $59.1M raise · filed Dec 2017

Co-investorsFrazier Life Sciences

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)inNicholas Downing(Director)

Board seatJeb Keiper· per SEC Form D · $10M raise · filed Nov 2019

Co-investorsBain Capital Life SciencesBain CapitalNEA SecondaryPolaris Partners

BiotechCambridge, US

Alexandra Glucksmann(Executive Officer, Director)Dominik Naczynski(Director)Chris Bowden(Director)Jake Simson(Director)Rosana Kapeller(Director)

Board seatAbbie CelnikerNeil Exter· per SEC Form D · $82.6M raise · filed Oct 2021

Co-investorsCasdin Capital

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)

Board seatRobert Tepper· per SEC Form D · $55.8M raise · filed Dec 2015

Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThe Column Group

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

BiotechTewksbury, US

George J. Fazio(Executive Officer, Director)Dan B. Curtis(Executive Officer)

BoardPaul LaViolette(Director)inGerald Brunk(Director)inIrit Yaniv(Director)

Board seatKevin GillisMark Levin· per SEC Form D · $11.1M raise · filed Jun 2025

Co-investorsAccelmed PartnersLumira VenturesSV Health Investors

Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.

Cambridge, US

Board seatNeil ExterCraig MuirKevin Starr· per SEC Form D

Co-investorsage1Samsara BioCapital

Jewel is a wearable patch cardioverter defibrillator designed to provide continuous protection from sudden cardiac arrest, using machine learning to minimize false alarms while requiring no daily maintenance for up to a week.

AI & Machine LearningHealthtechMedical DevicesSan Francisco, US

Uday N. Kumar(Executive Officer, Director)William Kucheman(Director)

BoardRussell Hirsch(Director)Krishna Yeshwant(Director)inWilliam H. Kucheman(Director)

Board seatNeil Exter· per SEC Form D

Co-investorsDeerfield Management CompanyGV (Google Ventures)

BiotechCambridge, US

Stephen Hurly(Executive Officer, Director)John McCabe(Executive Officer)Arthur P. DeCillis(Executive Officer)David A. Berry(Executive Officer, Director)Gregory D. Perry(Executive Officer)Eric S. Furfine(Executive Officer)

Board seatAbbie Celniker· per SEC Form D · $996K raise · filed Apr 2018

BiotechCambridge, US

Ed Freedman(Executive Officer, Director)

BoardCary Pfeffer(Executive Officer, Director)in

PartnerCary Pfeffer· quoted

Board seatCharles HomcyRobert Tepper· per SEC Form D

South San Francisco, US

John Schembri(Executive Officer)Ted W. Love(Executive Officer, Director)

BoardCharles Homcy, M.D.(Director)

Board seatKevin Starr· per SEC Form D

Co-investorsRA Capital

HealthtechCambridge, US

PETER THOMSON(Executive Officer)

BoardLOUIS BRENNER(Director)

Board seatAbbie CelnikerNeil Exter· per SEC Form D · filed Jul 2020

BiotechNew York, US

Joern Aldag(Executive Officer, Director)Reinhard Kandera(Executive Officer, Director)Paul-Henri Lambert(Director)Michael Kelly(Director)Julie O'Neill(Director)Sander van Deventer(Director)

Board seatChristoph Lengauer· per SEC Form D · filed Feb 2019

Co-investorsSofinnova Partners

BiotechInglewood, US

Anna M. Wu(Executive Officer, Director)Jeffrey D. Quan(Executive Officer)Benjamin Chen(Executive Officer)Valerie Calenda(Director)Anna W. Work(Director)Jennifer Keppler(President and Chief Operating Officer)

Board seatAbbie Celniker· per SEC Form D · $9.5M raise · filed Apr 2016

BiotechCambridge, US

Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)Richard Murray(Executive Officer, Director)

Board seatRobert KamenCary PfefferRobert Tepper· per SEC Form D

Co-investorsNextech Invest

Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa.

BiotechHealthtechHingham, US

Mark de Souza(Executive Officer, Director)Alexander Silver(Director)Hal Landy(Director)Joff Masukawa(Director)Deborah Ramsdell(Executive Officer, Director)

Board seatPhilip Reilly· per SEC Form D · $17.3M raise · filed Nov 2025

Ann Arbor-founded biopharmaceutical company developing small molecule immunomodulators for autoimmune diseases and cancer.

BiotechAnn Arbor, US

Paul Sekhri(Executive Officer)Gary Glick(Executive Officer, Director)Steve Gillis(Director)Kathleen M. Metters(Executive Officer, Director)

BoardMichael Hayden(Director)

Board seatRobert Kamen· per SEC Form D · filed Jun 2015

Co-investorsARCH Venture PartnersCanaan Partners

BiotechBoston, US

Gleb Kuznetsov(Executive Officer, Director)Pierce Ogden(Executive Officer, Director)

BoardJory Bell(Director)Jeff Huber(Director)Steven Holtzman(Director)

Board seatSteven J. Kafka· per SEC Form D · $32.8M raise · filed Dec 2024

BiotechSouth San Francisco, US

Tassos Anastasios Gianakakos(Executive Officer, Director)

BoardMark Perry(Director)Katherine Bowdish(Director)

Board seatCharles HomcyKevin Starr· per SEC Form D · $46M raise · filed Apr 2015

Co-investorsForesite CapitalKhosla Ventures

BiotechCambridge, US

Richard Gaynor, M.D.(Executive Officer)Robert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)Eric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Board seatRobert KamenRobert Tepper· per SEC Form D

Co-investorsNextech InvestSofinnova VenturesClal Biotechnology Industries

HealthtechBedford, US

Christopher von Jako(Executive Officer, Director)Eric Swanson(Director)Judith M. Huber(Executive Officer)Charles Carignan(Executive Officer, Director)

BoardRussell Hirsch(Director)

Board seatMark Levin· per SEC Form D · $40.7M raise · filed Nov 2015

Faction is a venture capital firm that invests in cryptocurrency and blockchain projects at the seed and series A stages, focusing on entrepreneurs building fundamental utility across the technology stack.

BiotechCrypto & Web3New York, US

Oren Harnevo(Executive Officer, Director)Ronald Bianchini, Jr.(Executive Officer, Director)Christina Calvaneso(Executive Officer)Brian Pozesky(Executive Officer)Jeff Fagel(Executive Officer)SAMANTHA SINGER(Executive Officer, Director)

Board seatDavid KaufmanAbbie Celniker· per SEC Form D · filed Dec 2023

Co-investorsAccelAdaverseAlephAxeleo CapitalBluebird VenturesBright Pixel Capital+36 more

BiotechMt. Arlington, US

Paul Chaney(Executive Officer, Director)Kevin Starr(Director)Lutz Giebel(Director)Colin Goddard(Director)

BoardDavid Guyer(Director)

Board seatAbbie Celniker· per SEC Form D · $47.3M raise · filed Apr 2019

Co-investorsAstellas Venture Management LLCAgent Capital

BiotechChestnut Hill, US

Joseph Italiano(Director)Jonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)

Board seatPhilip Reilly· per SEC Form D · $26.4M raise · filed Aug 2019

Co-investorsBoston Harbor AngelsQiming Healthcare

BiotechCambridge, US

Gad Soffer(Executive Officer)Ryan Cohlhepp(Executive Officer)J. Duncan Higgons(Director)Jeffrey Bluestone(Director)Dan Matloff(Executive Officer)Sanjay Keswani(Executive Officer, Director)

Board seatAbbie CelnikerCary Pfeffer· per SEC Form D · filed Nov 2018

Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.

BiotechHealthtechBoston, US

Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)

BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inTodd Foley(Director)

Board seatNeil Exter· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMed

BiotechHealthtechCambridge, US

Barry Greene(Executive Officer, Director)Kimi Iguchi(Executive Officer)Michael Cloonan(Executive Officer)Anne Marie Cook(Executive Officer)Stephen J. Kanes(Executive Officer)Jeffrey M. Jonas(Executive Officer, Director)

Board seatKevin Starr· per SEC Form D · $650M raise · filed Jan 2021

Septerna develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform.

BiotechDeep TechSouth San Francisco, US

Board seatJeffrey Tong· per SEC Form D · $150M raise · filed Jul 2023

Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalVertex Ventures HC

Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.

BiotechBoston, US

Jeb Keiper(Director)Ala Alenazi(Director)Pegah Ebrahimi(Director)Tasuku Kitada(Executive Officer, Director, Promoter)Samta Kundu(Executive Officer)Jory Bell(Director)

Board seatJeb Keiper· per SEC Form D · $120.1M raise · filed Mar 2026

Co-investorsJIC Venture Growth InvestmentsKinnevikPlayground GlobalAmgen VenturesANRIFPV+2 more

Terremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)

BoardMichael Goller(Director)Peter Thompson(Director)

Board seatReid Huber· per SEC Form D

Co-investorsEcoR1 CapitalOrbiMedRA CapitalNovo HoldingsOsage University Partners

Lexington, US

Board seatJigar Raythatha· per SEC Form D · $120.1M raise · filed Dec 2025

Co-investorsAtlas VentureOpenSky Ventures

Developer of Aqvesme (mitapivat), an FDA-approved medicine for anemia in thalassemia.

Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.

BiotechHealthtechMedical DevicesMassachusetts, US

Daniel Orlando(Chief Executive Officer)Tasos Konidaris(Executive Officer)Martin Paz(Executive Officer)Robert Gallotto(Executive Officer)Daniel Tasse(Executive Officer, Director)William Scheinler(Executive Officer)

Co-investorsHealthQuest CapitalBessemer Venture PartnersFrazier Life Sciences

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)in

Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+2 more

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossovervenBio PartnersVida Ventures

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

Gina Chapman(Executive Officer, Director)Anup Radhakrishnan(Executive Officer)Cassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny Venture

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LPCure VenturesVivo CapitalCatalio Capital ManagementNovo Holdings

Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.

Enterprise SoftwareGovTechSaaSNairobi, KE

Co-investors4Di CapitalInovia CapitalAgent CapitalBase10 PartnersCasdin CapitalInvus+3 more

Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.

Crypto & Web3Data & Infrastructure

Co-investorsDigital Currency GroupAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalInvus+3 more

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalBase10 PartnersCasdin Capital+5 more

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Jonathan Freeman(Interim CEO)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)

Co-investorsB Capital GroupB4 CapitalF-Prime CapitalAlexandriaB CapitalQatar Investment Authority+1 more

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(CEO & Founder)inDuane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)

BoardRobert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalGV (Google Ventures)HOF CapitalSoftBank Vision Fund+5 more

Moma Therapeutics is a biotechnology company developing precision medicines by targeting molecular machines that drive human disease.

Biotech

Co-investorsNextech InvestGoldman Sachs

A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.

BiotechDeep TechMedical DevicesWilmington, US

Liangxing Wu(Executive Officer, Director)Wenqing Yao(Executive Officer, Director)Ting Feng(Director)

BoardReid Huber(Director)in

Co-investorsNextech InvestThe Innovation Space

Originator of Inlexzo (gemcitabine intravesical system), an FDA-approved treatment for certain bladder cancers; acquired by Johnson & Johnson in 2019.